Trial Profile
A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms AVERT-2
- Sponsors Bristol-Myers Squibb
- 15 Nov 2023 Results evaluating the association of baseline circulated biomarkers with disease activity measures and their ability to predict clinical response in patients with early rheumatoid arthritis presented at the ACR Convergence 2023.
- 22 Apr 2023 Primary endpoint (Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24) has not been met, as per results published in the Arthritis Research and Therapy.
- 22 Apr 2023 Results of sub-analysis (patients treated with abatacept + methotrexate (n/N = 451/752)) assessing whether individual patients who achieved the week 24 Simplified Disease Activity Index remission primary endpoint could sustain remission to 1 year and then maintain it following changes in therapy, published in the Arthritis Research and Therapy.